Stock Scorecard
Stock Summary for Creative Medical Technology Holdings Inc (CELZ) - $5.56 as of 4/1/2024 8:42:25 PM EST
Total Score
12 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CELZ
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CELZ
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CELZ
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for CELZ
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for CELZ
Financial Details for CELZ
Company Overview |
|
---|---|
Ticker | CELZ |
Company Name | Creative Medical Technology Holdings Inc |
Country | USA |
Description | Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company is headquartered in Phoenix, Arizona. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/10/2024 |
Stock Price History |
|
Last Day Price | 5.56 |
Last Day Price Updated | 4/1/2024 8:42:25 PM EST |
Last Day Volume | 62,466 |
Average Daily Volume | 426,697 |
52-Week High | 13.30 |
52-Week Low | 3.93 |
Last Price to 52 Week Low | 41.48% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 61.37 |
Sector PE | 61.34 |
5-Year Average PE | -1.64 |
Free Cash Flow Ratio | 2.22 |
Industry Free Cash Flow Ratio | 18.52 |
Sector Free Cash Flow Ratio | 30.17 |
Current Ratio Most Recent Quarter | 27.65 |
Total Cash Per Share | 2.51 |
Book Value Per Share Most Recent Quarter | 7.53 |
Price to Book Ratio | 0.70 |
Industry Price to Book Ratio | 7.52 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 800.10 |
Industry Price to Sales Ratio Twelve Trailing Months | 9.88 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
Total Shares Outstanding | 1,382,100 |
Market Capitalization | 7,684,476 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 358.90% |
Annual Earnings Growth | 47.88% |
Reported EPS 12 Trailing Months | -3.76 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -3.06 |
Net Income Twelve Trailing Months | -5,286,574 |
Net Income Past Year | -5,286,574 |
Net Income Prior Year | -10,144,044 |
Quarterly Revenue Growth YOY | -83.90% |
5-Year Revenue Growth | -40.86% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 3,466,867 |
Total Cash Past Year | 3,466,867 |
Total Cash Prior Year | 18,399,136 |
Net Cash Position Most Recent Quarter | 3,466,867 |
Net Cash Position Past Year | 3,466,867 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 697,602 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 10,343,796 |
Total Stockholder Equity Prior Year | 15,864,674 |
Total Stockholder Equity Most Recent Quarter | 10,343,796 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | False |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.16 |
MACD Signal | 0.20 |
20-Day Bollinger Lower Band | 3.63 |
20-Day Bollinger Middle Band | 4.70 |
20-Day Bollinger Upper Band | 5.77 |
Beta | 4.95 |
RSI | 56.55 |
50-Day SMA | 4.95 |
200-Day SMA | 44.74 |
System |
|
Modified | 4/3/2024 8:42:22 PM EST |